Outcome of the Board Meeting held on 30th May, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astonea Labs Limited reported standalone audited FY 2025-26 results with revenue from operations up 51.33% year-on-year to Rs.147.58 Crore, driven by third-party manufacturing orders and own brand expansion. However, profitability declined with EBITDA at Rs.13.80 Crore (down 8.73%) and PAT at Rs.4.52 Crore (down 15.51%) as the company invested in distribution channels and brand building. The board approved related party transactions worth Rs.34 Crore for FY 2026-27 with four entities including Damaira Pharmaceuticals (Rs.10 Cr) and terminated two key agreements effective July 1, 2026. A major fire incident on April 27, 2026 caused Rs.9.39 Crore loss to factory building, plant, machinery and stocks, with insurance claim pending. The company also invested Rs.6.25 Crore for 25.74% equity stake in Damaira Pharmaceuticals and incorporated a wholly-owned subsidiary Astonea LLC in Wyoming, USA. Consolidated financial results were deferred pending associate company information.
The strong revenue growth shows business momentum but margin compression signals short-term profitability pressure from strategic investments. The fire incident and agreement terminations may impact near-term operations, while the FY 2026-27 guidance of Rs.215 Crore revenue (45-55% growth) with improved margins indicates management confidence in recovering profitability.